Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Phase 3 Tremfya results are promising for plaque psoriasis and psoriatic arthritis

By Brian Buntz | May 6, 2021

Janssen logoJohnson & Johnson’s (NYSE:JNJ) pharmaceutical subsidiary Janssen has announced that its Tremfya (guselkumab) selective interleukin (IL)-23 inhibitor therapy led to durable, complete skin clearance in the majority of adults with moderate-to-severe plaque psoriasis (PsO) for up to five years.

The drug also showed substantial efficacy in treating active psoriatic arthritis (PsA) for up to one year.

A total of 55% of patients receiving Tremfya had complete skin clearance, while 85% had an Investigator’s Global Assessment (IGA) score of either 0 or 1 at week 252 in the Phase 3 trial. IGA is a five-point system for characterizing psoriasis severity. A score of zero indicates complete clearing, while a score of one is for “almost clear” skin.

With 2020 sales hitting $1.35 billion, Tremfya is the only interleukin (IL)-23 inhibitor that is FDA approved for both moderate-to-severe plaque psoriasis and psoriatic arthritis.

Janssen had concluded earlier that seven out of 10 plaque psoriasis patients taking Tremfya saw 90% clearer skin after 16 weeks of therapy.

In April, AbbVie (NYSE:ABBV) also filed an FDA submission for an (IL)-23 inhibitor known as Skyrizi (risankizumab) for PsA.

The company presented the data at the American Academy of Dermatology Virtual Meeting Experience 2021.

“People living with psoriatic disease can face a lifetime of physical pain and discomfort, which places a significant burden on their lives,” said Dr. Kristian Reich, a professor at the University Medical Center Hamburg-Eppendorf, Germany, in a statement. The recent clinical trial results “add to a growing body of evidence for this first-in-class IL-23 inhibitor treatment for moderate to severe plaque psoriasis and active psoriatic arthritis,” said Reich, who is also a Janssen consultant.

The drug is available as a subcutaneous injection. In two PsA trials known as DISCOVER-1 and -2, investigators periodically administered 100 mg of the drug.

Its FDA indication recommends administering the drug twice at four-week intervals before administering it every eight weeks.


Filed Under: Immunology
Tagged With: guselkumab, Johnson & Johnson, plaque psoriasis, psoriatic arthritis., Tremfya
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
A closer look at the potential of Takeda’s Takhzyro in pediatric hereditary angioedema study
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
AstraZeneca RQ Biotechnology
AstraZeneca paying up to $157M for broad-spectrum monoclonal antibodies against COVID
Pfizer
Pfizer ticks up on Street-beating Q1, lessens full-year guidance

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50